SAR443820 ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 6 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 3 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05237284 (ClinicalTrials.gov) | April 13, 2022 | 2/2/2022 | Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed by an Open-label Extension | Amyotrophic Lateral Sclerosis | Drug: SAR443820;Drug: Placebo | Sanofi | NULL | Recruiting | 18 Years | 80 Years | All | 261 | Phase 2 | United States;Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom |
| 2 | EUCTR2021-004156-42-SE (EUCTR) | 12/04/2022 | 13/12/2021 | Phase 2 study for SAR443820 in participants with amyotrophic lateral sclerosis (ALS) | A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants withamyotrophic lateral sclerosis, followed by an open-label extension | Amyotrophic lateral sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: SAR443820 Other descriptive name: RA15804589, C19061501-F, DNL788, DN2489, DN0002489 | Sanofi-aventis recherche & développement | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 261 | Phase 2 | France;United States;Canada;Belgium;Spain;Germany;Netherlands;United Kingdom;Italy;Japan;China;Sweden | ||
| 3 | EUCTR2021-004156-42-FR (EUCTR) | 23/03/2022 | 20/01/2022 | Phase 2 study for SAR443820 in participants with amyotrophic lateral sclerosis (ALS) | A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants withamyotrophic lateral sclerosis, followed by an open-label extension | Amyotrophic lateral sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: SAR443820 Other descriptive name: RA15804589, C19061501-F, DNL788, DN2489, DN0002489 | Sanofi-aventis recherche & développement | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 261 | Phase 2 | United States;France;Canada;Spain;Belgium;Netherlands;Germany;United Kingdom;Japan;Italy;China;Sweden | ||
| 4 | EUCTR2021-004156-42-NL (EUCTR) | 10/03/2022 | 21/12/2021 | Phase 2 study for SAR443820 in participants with amyotrophic lateral sclerosis (ALS) | A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants withamyotrophic lateral sclerosis, followed by an open-label extension | Amyotrophic lateral sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: SAR443820 INN or Proposed INN: - Other descriptive name: RA15804589, C19061501-F, DNL788, DN2489, DN0002489 | Sanofi-aventis recherche & développement | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 261 | Phase 2 | France;United States;Canada;Spain;Belgium;Germany;Netherlands;United Kingdom;Japan;Italy;China;Sweden | ||
| 5 | EUCTR2021-004156-42-ES (EUCTR) | 08/03/2022 | 30/12/2021 | Phase 2 study for SAR443820 in participants with amyotrophic lateral sclerosis (ALS) | A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension | Amyotrophic lateral sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: SAR443820 INN or Proposed INN: SAR443820 Other descriptive name: RA15804589, C19061501-F, DNL788, DN2489, DN0002489 | Sanofi-aventis recherche & développement | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 261 | Phase 2 | France;United States;Canada;Belgium;Spain;Netherlands;Germany;United Kingdom;Japan;Italy;China;Sweden | ||
| 6 | EUCTR2021-004156-42-BE (EUCTR) | 23/02/2022 | 22/12/2021 | Phase 2 study for SAR443820 in participants with amyotrophic lateral sclerosis (ALS) | A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants withamyotrophic lateral sclerosis, followed by an open-label extension | Amyotrophic lateral sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: SAR443820 Other descriptive name: RA15804589, C19061501-F, DNL788, DN2489, DN0002489 | Sanofi-aventis recherche & développement | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 261 | Phase 2 | United States;Spain;Italy;United Kingdom;France;Canada;Belgium;Poland;Netherlands;Germany;China;Japan;Sweden |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05630547 (ClinicalTrials.gov) | December 19, 2022 | 7/11/2022 | A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis | A Phase 2 Double-blind, Randomized, Placebo-controlled Study Evaluating the Effect of SAR443820 on Serum Neurofilament Levels in Participants With Multiple Sclerosis, Followed by an Open-label Long-term Extension Period | Multiple Sclerosis | Drug: SAR443820;Other: Placebo | Sanofi | NULL | Recruiting | 18 Years | 60 Years | All | 168 | Phase 2 | Belgium;Canada;China;France;Italy;Poland;Spain |
| 2 | EUCTR2022-000049-34-ES (EUCTR) | 21/07/2022 | 22/07/2022 | Phase 2 study of SAR443820 in participants with multiple sclerosis (MS) | A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long-term extension period | Multiple sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SAR443820 INN or Proposed INN: SAR443820 Other descriptive name: RA15804589, C19061501-F, DNL788, DN2489, DN0002489 | Sanofi-aventis recherche & développement | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 280 | Phase 2 | France;United States;Czechia;Canada;Belgium;Poland;Spain;Germany;Italy;China | ||
| 3 | NCT04982991 (ClinicalTrials.gov) | August 5, 2021 | 20/7/2021 | Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants | A Phase 1, Open-label, 3-treatment Period, 1-sequence, Cross-over Study of the Pharmacokinetics, Safety and Tolerability After Single Ascending Oral Doses of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants. | Multiple Sclerosis Healthy Subjects | Drug: RIPK1 inhibitor | Sanofi | NULL | Completed | 20 Years | 55 Years | All | 14 | Phase 1 | United Kingdom |